Compare VYX & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYX | MDXG |
|---|---|---|
| Founded | 1881 | 2006 |
| Country | United States | United States |
| Employees | 13500 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.9M | 530.2M |
| IPO Year | N/A | 2007 |
| Metric | VYX | MDXG |
|---|---|---|
| Price | $6.71 | $3.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $13.67 | $9.00 |
| AVG Volume (30 Days) | ★ 2.1M | 1.9M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $6.02 | $3.03 |
| 52 Week High | $14.67 | $7.99 |
| Indicator | VYX | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 43.19 | 47.00 |
| Support Level | $6.54 | $3.11 |
| Resistance Level | $7.26 | $7.39 |
| Average True Range (ATR) | 0.40 | 0.16 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 2.29 | 78.01 |
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in two reportable segments: Retail, and Restaurants. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The company derives maximum revenue from Retail segment. Geographically, the company operates in United States, Americas (excluding United States), Europe, Middle East and Africa, and Asia Pacific. It derives maximum revenue from United States.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.